(-0.03%) 5 467.90 points
(-0.35%) 38 976 points
(0.35%) 17 780 points
(0.37%) $81.13
(-3.23%) $2.67
(-0.88%) $2 310.20
(-0.27%) $28.79
(1.61%) $1 002.30
(0.27%) $0.936
(0.71%) $10.68
(0.38%) $0.791
(-0.21%) $87.31
Live Chart Being Loaded With Signals
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system...
Stats | |
---|---|
本日の出来高 | 29 400 |
平均出来高 | 0 |
時価総額 | 13 069.00 |
EPS | $-0.830 ( Q3 | 2023-11-13 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
0 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0 (0.00%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Gorgas Gregory D. | Buy | 92 000 | Stock Option (right to buy) |
2023-08-04 | Matsui Connie | Buy | 1 083 | Stock Option (right to buy) |
2023-08-04 | Blayney Douglas | Buy | 1 083 | Stock Option (right to buy) |
2023-08-04 | Reyes Gregory | Buy | 1 083 | Stock Option (right to buy) |
2023-08-04 | Emanuele Robert Martin | Buy | 1 083 | Stock Option (right to buy) |
INSIDER POWER |
---|
100.00 |
Last 64 transactions |
Buy: 4 184 534 | Sell: 89 374 |
Artelo Biosciences, Inc. 財務諸表
Annual | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-3.49 |
FY | 2022 |
収益: | $0 |
総利益: | $0 (0.00 %) |
EPS: | $-3.49 |
FY | 2021 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-3.19 |
FY | 2020 |
収益: | $0.00 |
総利益: | $0.00 (0.00 %) |
EPS: | $-1.995 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Artelo Biosciences, Inc.
Artelo Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing treatments to modulate the endocannabinoid system. Its product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment of inflammatory bowel disease and post-traumatic stress disorder (PTSD); and ART26.12, a fatty acid binding protein 5 inhibitor for treating breast and prostate cancer, neuropathic and nociceptive pain, and anxiety disorders, including PTSD. The company was formerly known as Reactive Medical, Inc. and changed its name to Artelo Biosciences, Inc. in April 2017. Artelo Biosciences, Inc. was incorporated in 2011 and is based in Solana Beach, California.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。